According to
Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:
1. Bristol Myers Squibb Co (NYSE:BMY)
The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: B, and AI: B.
Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 50, which is 14 points higher than the general drug manufacturer industry average of 36.
BMY passed 17 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 18.67% over the past year, underperforming other general drug manufacturer stocks by -17 percentage points.
Bristol Myers Squibb Co has an average 1 year
price target of $64.42, an upside of 11.87% from Bristol Myers Squibb Co's current stock price of $57.58.
Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Bristol Myers Squibb Co, 41.67% have issued a Strong Buy rating, 8.33% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Eli Lilly & Co (NYSE:LLY)
Eli Lilly & Co (NYSE:LLY) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year.
Learn more.
The Component Grade breakdown for Eli Lilly & Co (NYSE:LLY) is: Value: B, Growth: C, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: B.
Eli Lilly & Co (NYSE:LLY) has a Due Diligence Score of 62, which is 26 points higher than the general drug manufacturer industry average of 36.
LLY passed 25 out of 38 due diligence checks and has strong fundamentals. Eli Lilly & Co has seen its stock return 50.33% over the past year, overperforming other general drug manufacturer stocks by 15 percentage points.
Eli Lilly & Co has an average 1 year
price target of $1,293.73, an upside of 8.85% from Eli Lilly & Co's current stock price of $1,188.58.
Eli Lilly & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 15 analysts covering Eli Lilly & Co, 73.33% have issued a Strong Buy rating, 20% have issued a Buy, 0% have issued a hold, while 6.67% have issued a Sell rating, and 0% have issued a Strong Sell.
3. Biogen (NASDAQ:BIIB)
Biogen (NASDAQ:BIIB) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year.
Learn more.
The Component Grade breakdown for Biogen (NASDAQ:BIIB) is: Value: A, Growth: C, Momentum: B, Sentiment: C, Safety: B, Financials: B, and AI: C.
Biogen (NASDAQ:BIIB) has a Due Diligence Score of 46, which is 10 points higher than the general drug manufacturer industry average of 36.
BIIB passed 14 out of 33 due diligence checks and has strong fundamentals. Biogen has seen its stock return 47.16% over the past year, overperforming other general drug manufacturer stocks by 12 percentage points.
Biogen has an average 1 year
price target of $219.68, an upside of 10.31% from Biogen's current stock price of $199.15.
Biogen stock has a consensus Buy recommendation according to Wall Street analysts. Of the 19 analysts covering Biogen, 31.58% have issued a Strong Buy rating, 26.32% have issued a Buy, 36.84% have issued a hold, while 5.26% have issued a Sell rating, and 0% have issued a Strong Sell.